Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
Identifieur interne : 003848 ( Main/Exploration ); précédent : 003847; suivant : 003849Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
Auteurs : E R Marcotte [Canada] ; A. Chugh ; R K Mishra ; R L JohnsonSource :
- Peptides [ 0196-9781 ] ; 1998.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors), Animals, Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Dopamine (metabolism), Hormone Antagonists (pharmacology), MPTP Poisoning, MSH Release-Inhibiting Hormone (analogs & derivatives), MSH Release-Inhibiting Hormone (pharmacology), Male, Mice, Mice, Inbred C57BL, Nerve Degeneration (prevention & control), Neuroprotective Agents (pharmacology), Neurotoxins (antagonists & inhibitors), Neurotoxins (toxicity), Parkinson Disease, Secondary (metabolism), Parkinson Disease, Secondary (prevention & control), Pyrrolidinones (pharmacology), Receptors, Dopamine (drug effects).
- MESH :
- chemical , analogs & derivatives : MSH Release-Inhibiting Hormone.
- chemical , antagonists & inhibitors : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurotoxins.
- drug effects : Corpus Striatum, Receptors, Dopamine.
- metabolism : Corpus Striatum, Dopamine, Parkinson Disease, Secondary.
- chemical , pharmacology : Hormone Antagonists, MSH Release-Inhibiting Hormone, Neuroprotective Agents, Pyrrolidinones.
- prevention & control : Nerve Degeneration, Parkinson Disease, Secondary.
- chemical , toxicity : Neurotoxins.
- Animals, Disease Models, Animal, MPTP Poisoning, Male, Mice, Mice, Inbred C57BL.
Abstract
3(R)-[(2(S)-Pyrrolidinyl-carbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) is a peptidomimetic analog of Pro-Leu-Gly-NH2 (PLG or MIF-1) that has previously been demonstrated to be more potent and efficacious that MIF-1 in enhancing dopamine receptor activity. Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model. PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Whether the enhanced neuroprotective effect of PAOPA is due to dopamine receptor stimulation, or a result of reduced oxidative stress through normalization of dopamine turnover, remains to be determined.
PubMed: 9493876
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001796
- to stream PubMed, to step Curation: 001796
- to stream PubMed, to step Checkpoint: 001796
- to stream Ncbi, to step Merge: 002630
- to stream Ncbi, to step Curation: 002630
- to stream Ncbi, to step Checkpoint: 002630
- to stream Main, to step Merge: 003E41
- to stream Main, to step Curation: 003848
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)</title><author><name sortKey="Marcotte, E R" sort="Marcotte, E R" uniqKey="Marcotte E" first="E R" last="Marcotte">E R Marcotte</name><affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Ontario</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Chugh, A" sort="Chugh, A" uniqKey="Chugh A" first="A" last="Chugh">A. Chugh</name></author><author><name sortKey="Mishra, R K" sort="Mishra, R K" uniqKey="Mishra R" first="R K" last="Mishra">R K Mishra</name></author><author><name sortKey="Johnson, R L" sort="Johnson, R L" uniqKey="Johnson R" first="R L" last="Johnson">R L Johnson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9493876</idno><idno type="pmid">9493876</idno><idno type="wicri:Area/PubMed/Corpus">001796</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001796</idno><idno type="wicri:Area/PubMed/Curation">001796</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001796</idno><idno type="wicri:Area/PubMed/Checkpoint">001796</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001796</idno><idno type="wicri:Area/Ncbi/Merge">002630</idno><idno type="wicri:Area/Ncbi/Curation">002630</idno><idno type="wicri:Area/Ncbi/Checkpoint">002630</idno><idno type="wicri:doubleKey">0196-9781:1998:Marcotte E:protection:against:mptp</idno><idno type="wicri:Area/Main/Merge">003E41</idno><idno type="wicri:Area/Main/Curation">003848</idno><idno type="wicri:Area/Main/Exploration">003848</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)</title><author><name sortKey="Marcotte, E R" sort="Marcotte, E R" uniqKey="Marcotte E" first="E R" last="Marcotte">E R Marcotte</name><affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Ontario</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Chugh, A" sort="Chugh, A" uniqKey="Chugh A" first="A" last="Chugh">A. Chugh</name></author><author><name sortKey="Mishra, R K" sort="Mishra, R K" uniqKey="Mishra R" first="R K" last="Mishra">R K Mishra</name></author><author><name sortKey="Johnson, R L" sort="Johnson, R L" uniqKey="Johnson R" first="R L" last="Johnson">R L Johnson</name></author></analytic><series><title level="j">Peptides</title><idno type="ISSN">0196-9781</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors)</term><term>Animals</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Hormone Antagonists (pharmacology)</term><term>MPTP Poisoning</term><term>MSH Release-Inhibiting Hormone (analogs & derivatives)</term><term>MSH Release-Inhibiting Hormone (pharmacology)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Nerve Degeneration (prevention & control)</term><term>Neuroprotective Agents (pharmacology)</term><term>Neurotoxins (antagonists & inhibitors)</term><term>Neurotoxins (toxicity)</term><term>Parkinson Disease, Secondary (metabolism)</term><term>Parkinson Disease, Secondary (prevention & control)</term><term>Pyrrolidinones (pharmacology)</term><term>Receptors, Dopamine (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>MSH Release-Inhibiting Hormone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Neurotoxins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Dopamine</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Hormone Antagonists</term><term>MSH Release-Inhibiting Hormone</term><term>Neuroprotective Agents</term><term>Pyrrolidinones</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Nerve Degeneration</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Neurotoxins</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>MPTP Poisoning</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">3(R)-[(2(S)-Pyrrolidinyl-carbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) is a peptidomimetic analog of Pro-Leu-Gly-NH2 (PLG or MIF-1) that has previously been demonstrated to be more potent and efficacious that MIF-1 in enhancing dopamine receptor activity. Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model. PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Whether the enhanced neuroprotective effect of PAOPA is due to dopamine receptor stimulation, or a result of reduced oxidative stress through normalization of dopamine turnover, remains to be determined.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Hamilton (Ontario)</li></settlement><orgName><li>Université McMaster</li></orgName></list><tree><noCountry><name sortKey="Chugh, A" sort="Chugh, A" uniqKey="Chugh A" first="A" last="Chugh">A. Chugh</name><name sortKey="Johnson, R L" sort="Johnson, R L" uniqKey="Johnson R" first="R L" last="Johnson">R L Johnson</name><name sortKey="Mishra, R K" sort="Mishra, R K" uniqKey="Mishra R" first="R K" last="Mishra">R K Mishra</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Marcotte, E R" sort="Marcotte, E R" uniqKey="Marcotte E" first="E R" last="Marcotte">E R Marcotte</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003848 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003848 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9493876
|texte= Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9493876" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |